{"brief_title": "Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial", "brief_summary": "The purposes of this are: - To determine the highest doses of Taxol and Navelbine that we can safely give to patients; - To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF; - To determine whether the combination of Taxol, Navelbine and G-CSF is more effective than standard therapy in treating metastatic breast cancer and prolonging life;", "condition": ["Breast Cancer"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Paclitaxel", "Vinorelbine", "Trastuzumab", "Filgrastim"], "description": ["50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", "20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", "4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.", "5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment."], "arm_group_label": ["1", "1", "1", "1"], "criteria": "INCLUSION To be eligible, volunteers must: - Have stage IV carcinoma of the breast that has been microscopically confirmed - Be age > 18 - Be fully active or ambulatory with symptoms but able to do light work - Have a life expectancy of > 16 weeks - Be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis, spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or nitrosureas) and > 2 weeks from prior hormonal therapy - Have had one or less prior regimens for metastatic disease - Have measurable (bidimensionally) or evaluable disease that is in an area that has not been radiated EXCLUSION Patients are not eligible if they: - Have rapidly progressing liver or lung metastases or uncontrolled central nervous system metastases - Are medically unstable - Are pregnant, nursing or unwilling to employ adequate contraception - Have pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer - Have psychological, familial, sociological or geographical conditions that do not permit weekly medical follow-up and compliance with the study protocol - Have hypersensitivity to E. Coli-derived proteins, Filgrastim, or any of its components - Have had prior therapy with Navelbine", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Breast Neoplasms", "Paclitaxel", "Vinorelbine", "Trastuzumab"], "id": "NCT00041470"}